Cell Sheet-Based Gene Therapy Market Growth Is Accelerating As Industry Transformation Continues
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Cell Sheet-Based Gene Therapy Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The cell sheet-based gene therapy market size has experienced rapid growth in recent years. It is projected to expand from $0.68 billion in 2025 to $0.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.4%. This historical expansion can be linked to increasing advancements in tissue engineering research, the early adoption of regenerative medicine techniques, a rise in cell-based therapeutic studies, improvements in gene delivery technologies, and the broadening of translational research initiatives.
The cell sheet-based gene therapy market size is projected to experience rapid expansion in the coming years, reaching $1.34 billion by 2030 with a compound annual growth rate (CAGR) of 14.6%. This growth during the forecast period is driven by factors such as the increasing demand for localized regenerative therapies, a rise in clinical trials for gene-modified cell therapies, the broadening of oncology and cardiology applications, growing investments in advanced tissue engineering, and a heightened focus on precision regenerative medicine. Significant trends anticipated for this period include the wider adoption of multilayered and co-culture cell sheet technologies, an intensified focus on localized gene expression therapies, the increasing integration of regenerative medicine approaches, a greater utilization of stem-cell derived cell sheets, and an enhanced emphasis on tissue integration and longevity.
Download A Free Sample Report For Comprehensive Market Insights:
Cell Sheet-Based Gene Therapy Market Expansion Drivers: What Is Shaping Future Growth?
The escalating incidence of chronic and degenerative illnesses is anticipated to propel expansion within the cell sheet-based gene therapy market. These enduring conditions encompass cardiovascular ailments, neurodegenerative disorders, diabetes, and genetic conditions, all of which progressively harm tissues and organs, demanding continuous therapeutic intervention. The occurrence of such conditions is increasing, driven by aging populations and longer life expectancies across both established and developing economies. Cell sheet-based gene therapy offers support for regenerative treatment strategies for chronic and degenerative diseases by facilitating localized tissue repair and sustained gene delivery via layered living cell constructs, which can enhance tissue integration and long-term therapeutic results. For example, in April 2025, the International Diabetes Federation (IDF), a Belgium-based non-profit organization, stated that 589 million individuals globally were living with diabetes in 2024, a figure expected to climb to 853 million by 2050. Thus, the growing prevalence of chronic and degenerative diseases is fostering the growth of the cell sheet-based gene therapy market.
Cell Sheet-Based Gene Therapy Market Segment Breakdown: Which Categories Generate The Most Revenue?
The cell sheet-based gene therapy market covered in this report is segmented –
1) By Cell-Sheet Type: Monolayer Cell-Sheet Type; Co-Culture Cell-Sheet Type; Multilayered Cell-Sheet Type; Other Cell-Sheet Types
2) By Technology Type: Cell Sheet-Based Engineering Techniques; Gene Delivery Methods
3) By Source Type: Autologous; Allogenic; Stem-Cell Derived
4) By Application: Oncology; Ophthalmology; Genetic Disorders; Cardiology; Other Applications
5) By End-User: Hospitals And Clinics; Research And Academic Institutions; Biotech And Pharma Companies; Other End-Users
Subsegments:
1) By Monolayer Cell-Sheet Type: Cardiomyocyte Sheets; Epithelial Cell Sheets; Mesenchymal Stem Cell Sheets; Other Monolayer Cell Sheets
2) By Co-Culture Cell-Sheet Type: Fibroblast + Stem Cell Sheets; Endothelial + Smooth Muscle Cell Sheets; Other Co-Culture Combinations
3) By Multilayered Cell-Sheet Type: Triple-Layered Sheets; Double-Layered Sheets; Other Multilayered Configurations
4) By Other Cell-Sheet Types: Genetically Modified Cell Sheets; Hybrid Cell Sheets; Other Novel Or Experimental Sheets
Cell Sheet-Based Gene Therapy Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading companies within the cell sheet-based gene therapy market are concentrating on creating innovative solutions, notably autologous gene-corrected cell sheet products. These products aim to improve outcomes in regenerative medicine, boost treatment precision, and facilitate long-term tissue repair by integrating engineered cells with scaffold-free sheet constructs for precise gene delivery and wound healing. Autologous gene-corrected cell sheet products are defined as therapies where a patient’s own cells undergo ex vivo genetic modification, are then expanded into sheet constructs that maintain cell-to-cell interactions and extracellular matrix integrity, and subsequently applied directly to injured tissues to foster functional integration and lasting therapeutic effects. As an illustration, in April 2025, Abeona Therapeutics Inc., a US-based biopharmaceutical firm, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency, for zevaskyn (prademagene zamikeracel). This product is designed to manage wounds in both adult and pediatric patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn functions by delivering the active COL7A1 gene through genetically corrected cell sheets, achieving significant wound healing and pain relief with just one application, and supporting continuous type VII collagen expression at wound sites, thereby representing a major advance in regenerative therapy and setting a precedent for future innovations in cell sheet-based gene therapy.
Cell Sheet-Based Gene Therapy Market Key Players And Strategic Industry Positioning
Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.
Access The Complete Cell Sheet-Based Gene Therapy Market Report:
Cell Sheet-Based Gene Therapy Market Largest Region By Revenue And Market Share
North America was the largest region in the cell sheet based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell sheet-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
